Manufacturer
16 recalls in our database name Acella Pharmaceuticals, LLC as the manufacturing or recalling firm.
Of the 16 recalls from Acella Pharmaceuticals, LLC we have scored against our rubric, 8 (50%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 3 (19%) are Severe.
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
Acella Pharmaceuticals is recalling Naproxen oral suspension due to the presence of lead and lithium above specification levels. The recall affects 6,336 bottles distributed nationwide.
Acella Pharmaceuticals is recalling 4,680 five-hundred-count bottles of Doxycycline Hyclate Tablets USP 100 mg after stability testing found the lot did not meet dissolution specifications.
Acella Pharmaceuticals recalled 7,104 bottles of Sodium Sulfacetamide 10% Sulfur 5% Cleanser nationwide because the product contained less active ingredient than labeled. The recall was terminated in December 2025.
Acella Pharmaceuticals is recalling Sodium Sulfacetamide 10% Sulfur 4% Cleansing Pads because testing found the drug out of specification for potency at shelf-life expiration. 528 cartons distributed nationwide are affected.
Acella Pharmaceuticals is recalling Phenytoin Sodium Injection because the primary vial label is missing a barcode. The recall affects 637 cartons distributed nationwide.
Acella Pharmaceuticals is recalling Phenytoin Sodium Injection due to missing barcodes on vial labels. The recall affects 574 cartons distributed nationwide.
Acella Pharmaceuticals is recalling 154,726 bottles of NP Thyroid 15 tablets because they contain less active ingredient than labeled.
Acella Pharmaceuticals is recalling NP Thyroid 15 tablets because they contain less active ingredient than labeled. The recall covers bottles distributed nationwide.
Acella Pharmaceuticals is recalling NP Thyroid 15 tablets because they contain less active ingredient than labeled. The recall covers specific lots distributed nationwide.
Acella Pharmaceuticals is recalling 79,344 bottles of NP Thyroid 15 tablets because they contain less active ingredient than labeled.
Acella Pharmaceuticals is recalling NP Thyroid 15 tablets because they contain less active ingredient than labeled. The recall covers bottles distributed nationwide.
Acella Pharmaceuticals is recalling NP Thyroid 15 tablets because FDA analysis found the levothyroxine content was less than the labeled claim.
Acella Pharmaceuticals is recalling NP Thyroid 15 tablets because FDA analysis found the levothyroxine content was less than labeled.
Acella Pharmaceuticals is voluntarily recalling 112,140 bottles of NP Thyroid 15 tablets because the drug is superpotent. The recall covers distribution across the US and Puerto Rico.
Acella Pharmaceuticals is voluntarily recalling 29,304 bottles of NP Thyroid 15 tablets because the drug is superpotent. The recall covers products distributed nationwide in the US and Puerto Rico.
Acella Pharmaceuticals is voluntarily recalling 49,128 bottles of NP Thyroid 15 tablets because they are superpotent. The FDA classified this as a Class I recall.